Scientists analyze HIV drug levels in kids to improve dosing

NCT ID NCT03194165

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined blood samples from 65 children aged 0 to 18 who were taking common HIV medications. The goal was to create computer models that show how these drugs behave in children, helping doctors adjust doses for each child's age, weight, and other factors. The research did not test new drugs but aimed to make existing treatments safer and more effective for kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
antiretroviral drugs (dolutegravir, raltegravir, rilpivirine, nevirapine, atazanavir, darunavir, ritonavir)
What this could lead to
If successful, this could help doctors give more accurate doses of HIV medicines to children based on age, weight, and other factors.
What could go wrong
This is a small, completed study that only looked at existing blood test data. It does not test a new treatment, so any dosing recommendations would need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cochin Hospital

    Paris, Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.